Requested Regulatory Flexibility Clause Samples

Requested Regulatory Flexibility. The proposed project will require specific regulatory relief from the reporting and signatory requirements of 40 CFR §270.11, in addition to reporting flexibility from several NMED Bureaus. The web-based system will not eliminate any regulatory reporting requirement; only modify the current format, delivery method, and archival procedures. NASA proposes that the regulatory flexibility issues requested in this proposal do not require specific regulatory relief and will be obtained through permit modifications, NMED Bureau-initiated changes, and/or mutually agreeable changes to current practices. NASA requests the following regulatory relief from the EPA (regulatory citations in bold-request for regulatory relief in italics):
View SourceView Similar (2)
Requested Regulatory Flexibility. EPA, with the assistance of NMED and NASA, will perform a legal analysis of EPA-administered environmental regulations that apply to NASA’s facility, to determine which current information-related requirements (if any) will require regulatory modification to implement this project. Such requirements could include, for example, the signatory requirements for RCRA permit applications, modifications and reports (40 CFR §270.11, §270.42(a)(i)). Based on this analysis, EPA will initiate two multi-media rulemakings effort to promulgate any regulatory changes necessary to facilitate this project. The first rulemaking will cover submissions on CD-ROM , the second rulemaking will cover web based submissions for compliance purposes in phases 3 through 6. It is expected that such a final rulemaking will enable an electronic deliverable and secure digital signature system to provide all affected EPA offices with the flexibility to legally receive electronic deliverables with digital signatures for all environmental compliance requirements. NASA proposes that compliance documentation will not be submitted to a centralized data receipt center; rather a centralized “hub” on the Internet where e-mail notifications with hypertext links will guide the recipient to the specific document. All documentation and reports submitted to NMED have individual formats that were determined by NASA, and are forwarded to different personnel within several separate Bureaus. The web-based system will not eliminate any regulatory reporting requirement; only modify the current format, delivery method, and archival procedures. The NASA proposal for web-based electronic deliverables and digital signatures is provided in Section 3.2.4. Actual “submittal” of the signature and certification requirements is proposed as an e-mail notification with hypertext links to the web-based documents, and will include a date/time stamp to document receipt, a secure digital signature, and the certification statement. In addition to any regulatory changes that may be needed for this project, EPA and NMED, in consultation with NASA, will also amend or modify other existing documents (e.g., permits, enforcement orders) and policies that now require submission of information in hard copy, to instead allow electronic reporting of such information and documentation. Such changes may require modifications to existing permits, orders or other documents or agreements. Specific examples of such information requirements ...
View Source

Related to Requested Regulatory Flexibility

  • Required Regulatory Approvals (a) The obligations of each Party under this Agreement are expressly contingent upon (i) each Party receiving all licenses, permits, permissions, certificates, approvals, authorizations, consents, franchises and releases from any local, state, or federal regulatory agency or other governmental agency or authority (which may include, without limitation and as applicable, the NYISO and the PSC) or any other third party that may be required for such Party in connection with the performance of such Party’s obligations under or in connection with this Agreement (the “Required Approvals”), (ii) each Required Approval being granted without the imposition of any modification or condition of the terms of this Agreement or the subject transactions, unless such modification(s) or condition(s) are agreed to by both Parties in their respective sole discretion, and (iii) all applicable appeal periods with respect to the Required Approvals having expired without any appeal having been made or, if such an appeal has been made, a full, final and non-appealable determination having been made regarding same by a court or other administrative body of competent jurisdiction, which determination disposes of or otherwise resolves such appeal (or appeals) to the satisfaction of both Parties in their respective sole discretion. (b) If any application or request is made in connection with seeking any Required Approval and is denied, or is granted in a form, or subject to conditions, that either Party rejects, in its sole discretion, as unacceptable, this Agreement shall terminate as of the date that a Party notifies the other Party of such denial or rejection, in which event the obligations of the Parties under this Agreement shall cease as of such date and this Agreement shall terminate, subject to NYSEG’s obligation to pay National Grid in accordance with the terms of this Agreement (including, without limitation, Section 10.3 above) for all Reimbursable Costs. All of National Grid’s actual costs in connection with seeking Required Approvals shall be included within the meaning of the term Reimbursable Costs and shall be paid for by NYSEG.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • Proposing Integration Activities in the Planning Submission No integration activity described in section 6.3 may be proposed in a CAPS unless the Funder has consented, in writing, to its inclusion pursuant to the process set out in section 6.3(b).

  • Financial Viability and Regulatory Compliance 2.6.1 Contractor warrants and represents that its corporate entity is in good standing with all applicable federal, state, and local licensing authorities and that it possesses all requisite licenses to perform the services required by this contract. Contractor further warrants and represents that it owes no outstanding delinquent federal, state or local taxes or business assessments. 2.6.2 Contractor agrees to promptly disclose to the MPHA any IRS liens or licensure suspension or revocation that may adversely affect its capacity to perform the services outlined within this contract. The failure by Contractor to disclose such issue to the MPHA in writing within 5 days of such notification received will constitute a material breach of this contract. 2.6.3 Contractor further agrees to promptly disclose to the MPHA any change of more than 50% of its ownership and/or any declaration of bankruptcy that Contractor may undergo during the term(s) of this contract. The failure of Contractor to disclose any change of more than 50% of its ownership and/or its declaration of bankruptcy within 5 days of said actions shall constitute a material breach of this contract. 2.6.4 All disclosures made pursuant to this section of the contract shall be made in writing and submitted to MPHA within the time periods required herein.

  • REGULATORY ADMINISTRATION SERVICES BNY Mellon shall provide the following regulatory administration services for each Fund and Series:  Assist the Fund in responding to SEC examination requests by providing requested documents in the possession of BNY Mellon that are on the SEC examination request list and by making employees responsible for providing services available to regulatory authorities having jurisdiction over the performance of such services as may be required or reasonably requested by such regulatory authorities;  Assist with and/or coordinate such other filings, notices and regulatory matters and other due diligence requests or requests for proposal on such terms and conditions as BNY Mellon and the applicable Fund on behalf of itself and its Series may mutually agree upon in writing from time to time; and